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© 2015 Japanese Society of Hepato-Biliary-Pancreatic SurgeryAbstract Over the past few years, knowledge regarding the
molecular pathology of sporadic pancreatic neuroendocrine
tumors (PNETs) has increased substantially, and a number
of targeted agents have been tested in clinical trials in this
tumor type. For some of these agents there is a strong biolog-
ical rationale. Among them, the mammalian target of
rapamycin inhibitor Everolimus and the antiangiogenic agent
Sunitinib have both been approved for the treatment of
PNETs. However, there is lack of knowledge regarding
biomarkers able to predict their efficacy, and mechanisms of
resistance. Other angiogenesis inhibitors, such as Pazopanib,
inhibitors of Src, Hedgehog or of PI3K might all be useful
in association or sequence with approved agents. On the other
hand, the clinical significance, and potential for treatment of
the most common mutations occurring in sporadic PNETs,
in the MEN-1 gene and in ATRX and DAXX, remains uncer-
tain. The present paper reviews the main molecular changes
occurring in PNETs and how they might be linked with treat-
ment options.
Keywords Genetics · Molecular · Mutation · Pancreatic
neuroendocrine tumors · Targeted therapy
Introduction
In the past decade, knowledge regarding molecular pathol-
ogy of sporadic pancreatic neuroendocrine tumors (PNETs)
has increased substantially, thanks to microarray studies
and novel mutational analysis methods [1]. Over the same
period of time, a number of targeted agents have been tested
in clinical trials in this tumor type. For some of these agents
there is a strong biological rationale. Among them, theG. Capurso · L. Archibugi · G. Delle Fave (✉)
Digestive and Liver Disease Unit, Faculty of Medicine and Psychology,
Sapienza University of Rome at S. Andrea Hospital, Rome, Italy
e-mail: gianfranco.dellefave@uniroma1.itmammalian target of rapamycin (mTOR) inhibitor
Everolimus (Afinitor, Novartis, Basel, Switzerland) and the
antiangiogenic agent Sunitinib are approved for the treat-
ment of PNETs. However, there is lack of knowledge
regarding biomarkers able to predict their efficacy, and about
mechanisms of resistance to these targeted agents [2]. It has
also been ascertained that the most common mutations in
sporadic PNETs are of the multiple endocrine neoplasia type
1 (MEN1) gene and of the genes ATRX and DAXX.
However the clinical significance and potential for treatment
of these mutations are uncertain. The present paper will re-
view the main molecular changes occurring in PNETs and
how they might be linked with treatment options.MENIN
MENIN is a nuclear protein, encoded by the MEN1 gene,
which regulates gene transcription by coordinating chromatin
remodeling. It is involved in the negative modulation of cell
cycle inhibitors, such as p27KIPI and p18INK4c, of transcrip-
tion factors such as SMAD3 and JUND, and interacts with the
DNA repair machinery [3]. MENIN is considered a tumor
suppressor, although its exact role is not completely clear
and its action is often controversial. In fact, MENIN works
as an inhibitor of proliferation, maintaining the pro-
moter activity of CDKN2C (p18) and CDKN1B (p27)
through H3K4 methylation, thus regulating the expression
of cell cycle progression inhibitors [3, 4]. Nevertheless, under
physiological or pathological conditions, such as obesity or
pregnancy, MENIN stimulates pancreatic endocrine cell
proliferation controlling G1 to S progression [5, 6].
While the role of MENIN has been extensively investi-
gated in patients with MEN1 syndrome, mutations of the
MEN1 gene have also been found in about 25–44% of spo-
radic PNETs [7, 8], suggesting a role in the pathogenesis of
these tumors. Interestingly, MEN1 mutations have been asso-
ciated with prolonged survival in patients with metastatic
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quent alterations in sporadic PNETs, this does not represent
a target for treatment yet, although there have successful
attempts of gene therapy to replace the MEN1 gene in
PNETs models. However, the relation between MENIN
and other “druggable” pathways is gaining increasing inter-
est. MENIN is able to suppress Akt activity reducing its
translocation from the cytoplasm to the cell membrane dur-
ing stimulation with growth factors, therefore reducing Akt-
induced proliferation and anti-apoptosis activity [9]. On the
other hand, MENIN expression is modulated by PI3K/Akt
activity, which leads to phosphorylation of the transcription
factor Foxo1, which in turn negatively regulates the expres-
sion of MENIN, enhancing proliferation [5, 10].
MENIN has also a role in preventing the RAS-driven
activation of the mitogen-activated protein kinase (MAPK)
pathway, leaving the RASSFA inhibitory pathway intact.
The removal of this mechanism of MAPK pathway blockage
could explain why the loss of MENIN causes proliferation in
PNETs [11]. However, targeting the RAF or MAPK pathway
alone does not seem a promising strategy in PNETs [12].
Recently, a novel link between MENIN and the Hedgehog
(Hh) signaling pathway has been suggested by Gurung et al.
[13]. Furthermore, Fendrich et al. showed how Cyclopamine,
a Hedgehog inhibitor, decreased tumor cell proliferation,
reduced tumor volume and significantly prolonged median
survival in the transgenic mouse model of PNET [14]. The
orally available smoothened antagonist LDE225 is therefore
under investigation for PNETs. Finally, a valuable target
therapy for MENIN could possibly arrive with RNA
antagomir(s)-based strategies, as suggested by Luzi et al.,
but further studies are needed to explore this field [15].ATRX and DAXX and epigenetics changes in PNETs
In the past few years, the possibility to use novel technologies
of DNA sequencing has led to a dramatic progress of
knowledge of the mutational status of human cancers. Next-
generation sequencing permits to identify single nucleotide mu-
tations of either the whole genome or of the exomes. The first
application of high throughput exomic sequencing of PNETs
[8] demonstrated that, after those of the MEN1 gene, the most
common mutations were of the alpha-thalasemia/mental
retardation syndrome, X-linked (ATRX), and death
domain-associated protein (DAXX) genes. Of 68 PNETs
cases investigated, 42% had mutation of one of these two
genes, and these were mutually exclusive (Table 1). The muta-
tions were associated with better clinical outcome. These find-
ings have raised interest on the significance of ATRX and
DAXX in PNETs. ATRX is a nuclear protein belonging to
the family of chromatin remodeling proteins, whose germinalmutations cause the alpha-thalasemia syndrome [16]. ATRX
is able to recognize the methylation status of histones, and
cooperates with DAXX in determining histones deposition.
Subsequent studies have confirmed that ATRX and
DAXX mutations are frequent in PNETs, and that mutations
correspond with decreased protein expression at immunohis-
tochemistry [17–21].
The mechanism by which the loss of ATRX or DAXX
favors tumor cells seems related with telomerase activity.
Over the course of life, telomeres progressively become
shorter with cell division, and the progressive loss of
telomeric DNA leads to cell senescence and death. Tumor
cells develop mechanisms of resistance to senescence, includ-
ing the reactivation of telomerase [22]. However, some
tumors lack telomerase activity, and display another,
telomerase-independent, peculiar mechanism of resistance to
cell senescence and death, named “Alternative Lengthening
of Telomeres” (ALT) [23]. Interestingly, human cancer cell lines
that display the “ALT pathway” are characterized by ATRX
mutations [24]. The association between ATRX/DAXX muta-
tions or their decreased expression, and the “ALT pathway”
was confirmed by three different studies conducted in spo-
radic or MEN1 associated PNETs [17, 18, 21]. In the last of
these studies, Marinoni et al. also associated ATRX/DAXX
with chromosomal instability. A less recent study demon-
strated the absence of telomerase activity in 27 PNET patients
[25]. It is therefore likely, that PNETs cells tend to use almost
exclusively the “ALT pathway” and not the telomerases to
gain “immortality”. Future studies evaluating whether PNETs
without ATRX/DAXXmutations show telomerase activity or
other molecular changes, such as mutations at TERT pro-
moter might prove interesting.
Another puzzling finding is the lack of consistency regard-
ing the association between ATRX/DAXXmutations and the
clinical outcome of PNET patients (Table 1). The absence of a
clear clinical significance and the difficulties in targeting the
“ALT pathway” also limit the clinical potential of these
findings. Indeed, while a number of agents, such as imetelstat,
are able to target telomerase, there are few data regarding the
development of efficient ALT inhibitors [26]. On the other
hand, knowledge regarding ATRX and DAXX and their
interaction with histones and telomeres has attracted many
researchers, and more attention to modifications occurring in
histones, chromatin remodeling, and epigenetics might help
define other potential targets for treatment, as methylation of
different genes has been associated with negative outcome
in PNETs [27].
Angiogenesis in PNETs
A rich vascularization is a typical feature of PNETs, and often
allows radiological differential diagnosis with pancreatic
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sis switch in human cancer has been extensively described
in a PNET transgenic mouse model (Rip1-Tag2) [28]. The
vascular endothelial growth factor (VEGF) and its receptor
VEGFR, as well as the platelet-derived growth factor (PDGF)
and fibroblast growth factor (FGF) are expressed in PNET
cells and/or in the surrounding endothelia [29]. However,
there is no clear correlation between the expression of VEGF
or the microvascular density and the prognosis of PNET
patients. Indeed, some studies have found that expression of
VEGF correlates with a more aggressive tumor behavior
[30], while others found that malignant tumors show lower
VEGF expression than benign ones [31, 32]. These findings
have been recapitulated under the term “neuroendocrine para-
dox” [33], and might be explained by the fact that intense
microvascular density and VEGF expression are markers of
“well-differentiated” neoplasms, resembling normal islet cells
architecture. As pancreatic endocrine cells turn more aggres-
sive and lose their original features, or gain further molecular
changes, their rapid growth causes hypoxia, and activates the
hypoxia-inducible factors-1α (HIF-1α) pathway, leading to an
increase of endothelial proliferation eventually resulting in
changes of the normal vascular architecture.
From a clinical viewpoint, however, inhibition of
neoangiogenesis is a valid treatment approach for PNETs.
The main employed agents are either tyrosine kinase inhibi-
tors targeting the VEGFR and/or other receptors (PDGFR,
FGFR) or antibodies directed against VEGF itself. Among
tyrosine kinase inhibitors, the only one approved for clinicaluse in patients with advanced PNETs is Sunitinib (Sutent,
Pfizer, New York, NY, USA), which has activity against mul-
tiple targets including VEGFR, PDGFR, c-KIT, Flt-3 and
RET [34]. The efficacy and safety of Sunitinib had first been
demonstrated in a phase II study including both PNETs and
carcinoid tumors [35], with a median time to progression of
7.7months for patients with PNETs. The drug has been ap-
proved after publication of a large randomized controlled trial
of Sunitinib versus placebo. The study demonstrated an in-
creased progression-free survival (PFS) in patients receiving
Sunitinib (10.2 vs 5.4months). Overall survival was also im-
proved with Sunitinib. Severe side-effects (grade 3–4) were
observed in 12% and 10% of patients, respectively [36].
Among other tyrosine kinase inhibitors, Sorafenib
(Nexavar, Bayer Pharma AG, Berlin-Wedding, Germany), a
multiple kinase inhibitor targeting VEGFR2, PDGFR,
FGFR1 and RAF, has been poorly investigated as a single
agent in PNETs. Its combination with both everolimus or
bevacizumab in phase I and II trials showed clinical benefit
but unfavorable safety results [37, 38].
Pazopanib (Votrient, Glaxo Group, London, UK) is an
orally available angiogenesis inhibitor that targets VEGFR1,
2 and 3; PDGFRα and c-kit. Its activity as monotherapy
has been demonstrated in a phase II study in metastatic
gastroenteropancreatic neuroendocrine tumors. Stable disease
was observed in 56.8% of cases and partial response in
18.9%, with 11% grade 3–4 toxicity [39]. The median PFS
was 9.5months. Interestingly, the activity of Pazopanib was
significant also in patients pre-treated with targeted therapies.
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monoclonal antibody binding circulating VEGF, approved
for the treatment of colorectal cancer. There are few data re-
garding Bevacizumab as monotherapy for PNETs. Some inter-
esting results have been published for Bevacizumab-based
combined treatments. The combination of Bevacizumab with
temozolomide [40] resulted safe in a phase II study in progres-
sive, pre-treated patients, with 86% response rate (partial
response+ stable disease) in PNETs and a PFS of 14.3months.
The combination of Bevacizumab with metronomic capecita-
bine and Octreotide also achieved interesting results in a phase
II study of 45 patients, with partial response in 18% and a PFS
of 15months. PNETs seemed to respond better than non
pancreatic tumors [41]. Bevacizumab seems an interesting
agent for combination studies with other cytotoxic drugs.
There are no data regarding biomarkers predictive of
response to antiangiogenic agents. There are also few molec-
ular data explaining the occurrence of secondary resistance to
antiangiogenic agents, but it has been reported that after initial
response, evasive resistance might lead to a more aggressive
behavior [42]. This phenomenon might rely on progressive
selection of clones able to survive in a hypoxic environment,
and might be limited by combined treatments targeting differ-
ent players of the angiogenesis machinery.
The PI3K/Akt/mTOR pathway
The mammalian target of rapamycin (mTOR) is an intracel-
lular serine/threonine kinase working as a transduction
factor to which a wide variety of physiological and patho-
logic extra and intracellular signals converge. mTOR is in-
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OSoverall survival, PFS progression-free survivalproliferation and motility, through the regulation of protein
translation. Its function is carried out through the formation
of two complexes, mTORC1 and 2 [43]. mTORC1 regulates
mRNA translation and protein synthesis in response to
nutrients, hormones and growth factors. It acts through phos-
phorylation of the S6 kinase 1 (S6K1), which subsequently
phosphorylates the S6 ribosomal protein (S6rp) of the 40S
subunit, initiating protein synthesis, and the eukaryotic
initiation factor 4E (eIF4E) binding protein (4EBP1), which,
under normal conditions, inhibits cap-dependent translation
by binding eIF4E. Once phosphorylated, 4EBP1 releases
eIF4E and subsequently the cap-dependent mRNA transla-
tion of proteins initiates. This complex is sensitive to
rapamycin and its analogs [44]. mTORC2 is involved in
cell survival but also in cytoskeletal remodeling and cell
migration. The main substrates of mTORC2 are protein
kinase B (Akt) and protein kinase C. This complex is relatively
insensitive to rapamycin [44–46]. The expression and ac-
tivity of mTOR have been proved to be higher in PNETs
tissue than in normal pancreatic islet cells. Expression of
mTOR or of its activated downstream target p4EBP1 has
also been associated with a higher proliferative index and
shorter survival in patients with neuroendocrine tumors.
The expression of mTOR, p-mTOR and S6K is significantly
related to tumor aggressiveness in terms of mitotic count,
tumor size, staging, vascular invasion and metastasis [47].
Furthermore, low levels of 4EBP1 or high levels of eIF4E
are thought to confer resistance to rapamycin analogs [48].
Therefore, mTOR and its effectors might be biomarkers of
aggressive disease (Table 2), but are not mutated in PNETs,
with most molecular changes occurring upstream on the
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works downstream of many growth factors, such as insu-
lin or insulin-like growth factors (IGF-1) and their recep-
tors. Upon phosphorylation of receptor’s substrates, such as
IRS, PI3K is recruited to the cell membrane and turns
phosphatidylinositiol-4,5-bisphospate (PIP2) to phosphatidlino-
siytiol-3,4,5-bisphospate (PIP3), and eventually these changes
result in activation of Akt. In this process, the antagonist of
PI3K is PTEN, a phosphatase that turns PIP3 to PIP2. PTEN
is mutated or lost in about 10–29% of sporadic PNETs [49,
50]. The expression of PTEN in PNETs has been positively cor-
related with longer survival especially when correlated with low
expression of p-mTOR [49]. The PI3K-Akt pathway is linked
to mTOR through the tuberous sclerosis proteins TSC1
(hamartin) and TSC2 (tuberin) that act as negative regulators
of the mTOR signaling: when phosphorylated by Akt TSC2
gets inactivated, unblocking the mTOR activator GTPase Rheb.
In sporadic PNETs, somatic mutations of genes involved
in the mTOR pathway has been identified in 16% of cases,
including PTEN, TSC2 and PIK3CA [17, 29]. Particularly,
PTEN was found mutated in 7%, TSC2 in 8.8% and PIK3CA
in only 1.4% [8]. Moreover, lower protein levels of TSC2 and
PTEN are related to shorter disease-free and overall survival
[51]. All these findings support the relevance of the mTOR
pathway as potential therapeutic target for PNET (Table 2).
However, biomarkers to select individual patients who would
respond to treatment with mTOR inhibitors are lacking.
The activity of the mTORC1 inhibitor Everolimus on
PNETs has been explored in the RADIANT-1 phase II trial,
on 160 patients, 45 of whom also received concurrent
treatment with octreotide. The combination of the two drugs
increased the median PFS compared to those receiving
everolimus alone. In the RADIANT-3 trial, a phase III
placebo-controlled trial of 410 patients with advanced
PNETs, Everolimus monotherapy was compared with pla-
cebo. The results showed a significant prolongation in median
PFS in the Everolimus arm (11 vs 4.6months). The result of
this trial led to approval of Everolimus by FDA and EMA for
the treatment of locally advanced, metastatic or unresectable
PNETs [52]. The most common grade 3/4 adverse events were
stomatitis (7%), anemia (6%), hyperglycemia (5%), and pneu-
monitis. Similar results in terms of activity and adverse events
have been reported in non-controlled studies [53].
Temsirolimus is another rapamycin analog, also evaluated
in a phase II study on 37 patients with advanced, progressive
neuroendocrine tumors, with good results. About 50% of
patients achieved stable disease with a median PFS of
6months. It also appeared more active in PNET patients com-
pared to carcinoid (median PFS 10.6months in PNETs).
Primary or secondary resistance to treatment with Everoli-
mus has been linked with escape routes activating the
upstream PI3K/Akt pathway. These are thought to be due toinhibition of mTORC1 with consequent upregulation of
PDGFRs and IRS-1 through a negative feedback loop leading
to Akt activation. Rapamycin and Everolimus use, indeed, has
been found to increase Akt phosphorylation [54]. Although
phosphorylation of Akt is considered a part of the evasive
response to mTOR inhibitors, it has also been reported that
upon treatment with Everolimus, patients experiencing a par-
tial response are more likely to have an increase in p-Akt, both
before and during treatment. Further studies should confirm if
p-Akt might serve as a biomarker of sensitivity to Everolimus
rather than of secondary resistance [55].
Different strategies might overcome secondary resistance
to Everolimus. One is the combination of Everolimus with
other drugs, either acting on the same pathway (vertical inhi-
bition) or targeting another pathway (horizontal inhibition).
Another option could be a sequential treatment, after failure
of the first one. A logical strategy to overcome resistance to
mTOR inhibitors is, indeed, to use other inhibitors able to
block targets upstream of mTOR, such as Akt or PI3K. The
PI3K-inhibitor that attracted researchers the most was
BEZ235 for its dual inhibition activity of PI3K and
mTORC1/2. In a recent study, a combined treatment with
BEZ235 and Everolimus at low doses resulted as more effec-
tive compared to the use of each drug alone, and was active in
cell line models of both primary and secondary resistance to
Everolimus [56]. However, clinical trials testing BEZ235 effi-
cacy and safety compared to Everolimus, or its activity after
failure of Everolimus, have been stopped for side-effects.
Other “druggable” molecular alterations
Another regulator of the PI3K/Akt and the MAPKs pathways
is EGFR (ErbB-1), a member of the ErbB family of tyrosine
kinase receptors. PNET patients with activated EGFR exhibit
a worse prognosis [57]. EGFR activation results in a concom-
itant upregulation of downstream effectors such as Akt and
ERK [58]. More recently EGFR transactivation induced by
various GI hormones/neurotransmitters and mediated by
Src, was proven to have a role in PNET cells growth [59].
Gefitinib is a small molecule inhibitor of EGFR intracellular
domain. In vitro studies showed its activity with a dose-
dependent reduction of cell viability and increased apoptosis
in PNET cells [60]. Clinical studies with gefitinib showed a
30–60% of PFS at 6months, though with rare remissions
[61]. Other drugs directed towards this target are the anti-
HER-2 antibody Pertuzumab or the anti-EGFR Erlotinib,
but phase II trials with pertuzumab and erlotinib were termi-
nated due to extreme toxicity.
The Src Family of Kinases (SFK) is a family of non-
receptor tyrosine kinases involved in the transduction of sig-
nals from the cell membrane to different targets involved in
cell cycle, cell adhesion and cell motility. SFKs were found
J Hepatobiliary Pancreat Sci (2015) 22:594–601 599to be overexpressed in PNETs [62] and have a role in EGFR
transactivation [59]. Inhibiting its activity decreases adher-
ence, spreading and migration of PNET cells [63]. Further-
more, SFKs control mTOR activity during adhesion and
concurrent inhibition of SFKs and mTOR reduced prolifera-
tion of PNET cells without inducing PI3K/Akt activity [64].
It was also found how Src has a role in stem cells isolated from
intestinal carcinoid cells [65], confirming its likely relevant
role as possible co-treatment.Conclusion
As compared with only a decade ago, the knowledge regard-
ing the molecular pathogenesis of sporadic PNETs has sub-
stantially improved, in parallel with an increase of high
quality clinical studies exploring “targeted” agents. However,
there is a lot to do, to obtain reliable in vitromodels on which
accurate preclinical investigations might be performed. Such
studies should help define whether the combination of dif-
ferent drugs, or a rational sequence of different targeted agents
may overcome acquired resistance to single targeted agents.
Finally, biomarkers predictive the sensitivity or resistance of
individual patients in clinical practice are lacking, and knowl-
edge on the role of the most common mutations is unclear.Conflict of interest None declared.References
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